A Phase I, Open-Label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Anti-Tumor Activity of RO7617991 in HLA-A*02-Positive Patients With Locally Advanced and/or Metastatic MAGE-A4-Positive Solid Tumors
Latest Information Update: 04 Sep 2024
At a glance
- Drugs RO 7617991 (Primary) ; Tocilizumab (Primary)
- Indications Malignant melanoma; Solid tumours
- Focus Adverse reactions
- Sponsors Genentech
Most Recent Events
- 02 Sep 2024 Status changed from recruiting to withdrawn prior to enrolment.
- 02 Aug 2024 Planned initiation date changed to 30 Sep 2024.
- 08 Jul 2024 Planned primary completion date changed from 1 Feb 2028 to 31 Jul 2024.